Marco Sabatini - Academia.edu (original) (raw)
Uploads
Papers by Marco Sabatini
Pulmonary Pharmacology & Therapeutics, 2013
Some clinical trials have suggested that the inhaled long-acting b 2 -agonists (LABAs) may be eff... more Some clinical trials have suggested that the inhaled long-acting b 2 -agonists (LABAs) may be effective in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Since indacaterol, the first once-daily LABA to be developed for the regular treatment of COPD, exhibits fast onset of action and 24-h duration of bronchodilation, we have investigated its effects in patients with AECOPD managed in the emergency department.
Pulmonary Pharmacology & Therapeutics, 2013
Some clinical trials have suggested that the inhaled long-acting b 2 -agonists (LABAs) may be eff... more Some clinical trials have suggested that the inhaled long-acting b 2 -agonists (LABAs) may be effective in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Since indacaterol, the first once-daily LABA to be developed for the regular treatment of COPD, exhibits fast onset of action and 24-h duration of bronchodilation, we have investigated its effects in patients with AECOPD managed in the emergency department.